BioMarin ‘turning the corner’ on profits with optimism on Voxzogo, Roctavian — but questions remain

Beth Snyder Bulik

Senior Editor

BioMarin finally is ‘turning the corner’ on profitability in 2022, CEO Jean-Jacques Bienaimé said in its earnings call yesterday. And while investors generally agreed with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BioMarin ‘turning the corner’ on profits with optimism on Voxzogo, Roctavian — but questions remain

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Bio­Marin ‘turn­ing the cor­ner’ on prof­its with op­ti­mism on Vox­zo­go, Roc­ta­vian — but ques­tions re­main

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

BioMarin ‘turning the corner’ on profits with optimism on Voxzogo, Roctavian — but questions remain